IndieBio is the world’s first synthetic biology accelerator, investing at the pre-seed/earliest institutional stage in sectors including. See contact routes.
IndieBio is the world’s first synthetic biology accelerator, investing at the pre-seed/earliest institutional stage in sectors including therapeutics, climate tech, agtech, biomaterials, and food innovation with typical checks of $250K–$3M (often $525K for the core program). Its distinctive thesis centers on using biology as an engineering tool to solve challenges in health, food, climate, and materials, specifically targeting scientists with breakthrough ideas but minimal proof of concept who are “too early” for traditional biotech investors. Notable portfolio companies include unicorns NotCo, Prellis Biologics, and MycoWorks, alongside exits and leaders like Geltor, Perfect Day, Memphis Meats (now Clover Meat), and Zymergen.
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like IndieBio · Full investor directory · Investor access · Company funding database